Dashboard
1
Poor Management Efficiency with a low ROCE of 8.99%
- The company has been able to generate a Return on Capital Employed (avg) of 8.99% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 13.42% and Operating profit at -4.13% over the last 5 years
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROE of 3.01%, it has a attractive valuation with a 2.13 Price to Book Value
5
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.39%
0%
-1.39%
6 Months
-4.94%
0%
-4.94%
1 Year
-2.72%
0%
-2.72%
2 Years
10.23%
0%
10.23%
3 Years
-23.66%
0%
-23.66%
4 Years
-40.28%
0%
-40.28%
5 Years
-16.11%
0%
-16.11%
Cathay Biotech, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.42%
EBIT Growth (5y)
-4.13%
EBIT to Interest (avg)
99.33
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0.18
Tax Ratio
15.23%
Dividend Payout Ratio
47.53%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.99%
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
71
Industry P/E
Price to Book Value
2.13
EV to EBIT
71.52
EV to EBITDA
39.11
EV to Capital Employed
3.40
EV to Sales
8.75
PEG Ratio
2.00
Dividend Yield
0.63%
ROCE (Latest)
4.76%
ROE (Latest)
3.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
874.30
895.00
-2.31%
Operating Profit (PBDIT) excl Other Income
130.80
189.30
-30.90%
Interest
0.90
0.70
28.57%
Exceptional Items
3.50
2.20
59.09%
Consolidate Net Profit
138.70
172.50
-19.59%
Operating Profit Margin (Excl OI)
149.60%
123.70%
2.59%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -2.31% vs 15.36% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -19.59% vs 38.78% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,948.00
2,109.20
39.77%
Operating Profit (PBDIT) excl Other Income
675.90
440.30
53.51%
Interest
33.50
37.90
-11.61%
Exceptional Items
0.00
0.00
Consolidate Net Profit
474.60
408.50
16.18%
Operating Profit Margin (Excl OI)
118.90%
71.40%
4.75%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 39.77% vs -13.35% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.18% vs -33.33% in Dec 2023
About Cathay Biotech, Inc. 
Cathay Biotech, Inc.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available






